Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.

ABSTRACT: With advances in the discovery of the clinical and molecular landscapes of prostate cancer (PCa), implementation of precision medicine-guided therapeutic testing in the clinic has become a priority. Patient derived organoids (PDOs) are three-dimensional (3D) tissue cultures that promise to enable the validation of preclinical drug testing in precision medicine and coclinical trials by modeling PCa for predicting therapeutic responses with a reliable efficacy. We evaluate the advances in 3D culture and PDO use to model clonal heterogeneity and screen for effective targeted therapies, with a focus on the technological advances in generating PDOs. Recent innovations include the utilization of PDOs both in original research and/or correlative studies in clinical trials to examine drug effects

SUBMITTER: Pamarthy S 

PROVIDER: S-EPMC8480086 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature